Article Versions Notes

Shalata W, Iraqi M, Bhattacharya B, Fuchs V, Roisman LC, Cohen AY, Massalha I, Yakobson A, Prasad M, Elkabets M, et al. Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). Cancers. 2021; 13(14):3630. https://doi.org/10.3390/cancers13143630

Shalata, Walid, Muhammed Iraqi, Baisali Bhattacharya, Vered Fuchs, Laila C. Roisman, Ahron Yehonatan Cohen, Ismaell Massalha, Alexander Yakobson, Manu Prasad, Moshe Elkabets, and et al. 2021. "Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma)" Cancers 13, no. 14: 3630. https://doi.org/10.3390/cancers13143630

Shalata, W., Iraqi, M., Bhattacharya, B., Fuchs, V., Roisman, L. C., Cohen, A. Y., Massalha, I., Yakobson, A., Prasad, M., Elkabets, M., Porgador, A., & Peled, N. (2021). Rapid Response to the Combination of Lenvatinib and Pembrolizumab in Patients with Advanced Carcinomas (Lung Adenocarcinoma and Malignant Pleural Mesothelioma). Cancers, 13(14), 3630. https://doi.org/10.3390/cancers13143630